Metavision Arruzafa S.L.

This site in Cordoba, Spain is conducting a broad range of ophthalmology trials focused on eye diseases, with studies aimed at improving symptom control, preserving vision, and assessing the safety and effectiveness of new treatments.

• Studies in dry eye disease and meibomian gland dysfunction are evaluating ways to reduce discomfort and improve daily eye symptoms.
• Research in age-related macular degeneration and geographic atrophy is examining new approaches to slow disease progression and protect visual function.
• Trials in neovascular age-related macular degeneration and subretinal hyperreflective material are assessing treatment effectiveness and longer-term vision outcomes.

The research portfolio also includes work on Fuchs endothelial corneal dystrophy, thyroid eye disease, and atopic keratoconjunctivitis, reflecting a strong focus on both chronic retinal conditions and inflammatory eye disorders.

A major area of activity at this hospital/clinic is the study of degenerative retinal conditions, especially geographic atrophy secondary to age-related macular degeneration and related forms of dry AMD. These trials are designed to test new therapies and better understand how to preserve sight over time.

• Investigations of geographic atrophy are focused on limiting lesion growth and maintaining remaining vision.
• Studies in dry age-related macular degeneration are exploring novel treatments that may help slow progression of advanced retinal damage.
• Work on subretinal hyperreflective material is aiming to clarify how treatment can improve retinal outcomes in affected patients.

This area of research highlights the site’s interest in both diagnostic understanding and therapeutic innovation for progressive macular disease.

The site is also active in trials linked to immune system diseases, especially conditions that affect the eyes through inflammation and immune dysregulation. These studies are exploring new treatments that may improve comfort, reduce inflammation, and support long-term eye health.

• Thyroid eye disease research is testing therapies intended to ease symptoms and improve safety and tolerability.
• Atopic keratoconjunctivitis studies are evaluating treatments for ocular itching and allergic eye inflammation.
• Dry eye and related inflammatory conditions are being studied to better control symptoms and inflammatory markers.

Together, these trials show a strong emphasis on immune-related ophthalmic disease and on finding more effective ways to manage chronic inflammatory eye conditions.

Research at Metavision Arruzafa S.L. also includes corneal disease trials that aim to improve visual recovery and support better outcomes after eye procedures. These studies are looking at whether new therapies can enhance clarity of vision and recovery in patients with structural corneal disorders.

• Fuchs endothelial corneal dystrophy is being studied to improve corneal function and visual recovery.
• Trials involving post-procedure eye care are assessing whether treatments can accelerate improvement in best corrected visual acuity.
• These studies are focused on evaluating both safety and effectiveness in corneal disease management.

This part of the portfolio reflects a practical focus on restoring vision and supporting patients with corneal endothelial disease.